20132203

Source:http://linkedlifedata.com/resource/pubmed/id/20132203

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0010181, umls-concept:C0027462, umls-concept:C0030705, umls-concept:C0069805, umls-concept:C0087111, umls-concept:C0138666, umls-concept:C0388753, umls-concept:C0878773, umls-concept:C1099677, umls-concept:C2343853
pubmed:issue	4
pubmed:dateCreated	2010-7-26
pubmed:abstractText	To assess the cost-effectiveness of solifenacin vs other antimuscarinic strategies commonly used in UK clinical practice, based on the results of a recent published review.
pubmed:commentsCorrections	http://linkedlifedata.com/resource/pubmed/commentcorrection/20132203-20653664
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/100886721
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Benzhydryl Compounds, http://linkedlifedata.com/resource/pubmed/chemical/Benzilates, http://linkedlifedata.com/resource/pubmed/chemical/Cresols, http://linkedlifedata.com/resource/pubmed/chemical/Delayed-Action Preparations, http://linkedlifedata.com/resource/pubmed/chemical/Mandelic Acids, http://linkedlifedata.com/resource/pubmed/chemical/Muscarinic Antagonists, http://linkedlifedata.com/resource/pubmed/chemical/Phenylpropanolamine, http://linkedlifedata.com/resource/pubmed/chemical/Quinuclidines, http://linkedlifedata.com/resource/pubmed/chemical/Tetrahydroisoquinolines, http://linkedlifedata.com/resource/pubmed/chemical/fesoterodine, http://linkedlifedata.com/resource/pubmed/chemical/oxybutynin, http://linkedlifedata.com/resource/pubmed/chemical/propiverine, http://linkedlifedata.com/resource/pubmed/chemical/solifenacin succinate, http://linkedlifedata.com/resource/pubmed/chemical/tolterodine
pubmed:status	MEDLINE
pubmed:month	Aug
pubmed:issn	1464-410X
pubmed:author	pubmed-author:CardozoLindaL, pubmed-author:SidhuManpreetM, pubmed-author:ThorpeAndrewA, pubmed-author:WarnerJulietJ
pubmed:issnType	Electronic
pubmed:volume	106
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	506-14
pubmed:dateRevised	2011-11-17
pubmed:meshHeading	pubmed-meshheading:20132203-Benzhydryl Compounds, pubmed-meshheading:20132203-Benzilates, pubmed-meshheading:20132203-Cost-Benefit Analysis, pubmed-meshheading:20132203-Cresols, pubmed-meshheading:20132203-Decision Trees, pubmed-meshheading:20132203-Delayed-Action Preparations, pubmed-meshheading:20132203-Humans, pubmed-meshheading:20132203-Mandelic Acids, pubmed-meshheading:20132203-Muscarinic Antagonists, pubmed-meshheading:20132203-Phenylpropanolamine, pubmed-meshheading:20132203-Quality of Life, pubmed-meshheading:20132203-Quinuclidines, pubmed-meshheading:20132203-Tetrahydroisoquinolines, pubmed-meshheading:20132203-Treatment Outcome, pubmed-meshheading:20132203-Urinary Bladder, Overactive
pubmed:year	2010
pubmed:articleTitle	The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service.
pubmed:affiliation	Urogynaecology, Kings' College Hospital, London, UK.
pubmed:publicationType	Journal Article, Comparative Study, Research Support, Non-U.S. Gov't